Interferon alpha: Phase III

AMAR said its second U.S. Phase III trial of oral interferon alpha in 256 patients did not meet its primary end point of increasing SWS and reducing subjective measures of dry mouth. However, oral interferon did produce a significant improvement in UWS production compared to controls (p<0.05), and in patients with circulating autoantibodies the IFN-alpha group showed a significant improvement compared to controls (p=0.03). The 150 IU of interferon was given three times daily. ...